Sellas Life Sciences Stock Soars Ahead of Key AML Trial Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLS?
Source: stocktwits
- Clinical Trial Progress: As of December 26, 2025, Sellas Life Sciences has recorded 72 events in its AML trial, nearing the 80-event threshold required to trigger the final survival analysis, which may indicate longer patient survival and boosts market confidence in the company.
- Strong Stock Performance: SLS shares surged to a three-year high on Monday, closing at $5.31 on Tuesday with over a 5% gain, having finished in the green in 11 of the last 12 sessions, reflecting strong investor anticipation for the upcoming clinical data.
- Analyst Optimism: Koyfin consensus estimates show an average 12-month price target of $6.83 for SLS, implying a 29% upside from current levels, with analysts rating the stock as a 'Strong Buy', indicating a positive outlook for its future performance.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for SLS is deemed 'extremely bullish', with message volume rising 47% over the past 24 hours, highlighting heightened investor interest and confidence in the forthcoming trial results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.050
Low
7.00
Averages
7.25
High
7.50
Current: 5.050
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas Life Sciences Stock Soars Ahead of Key AML Trial Data
- Clinical Trial Progress: As of December 26, 2025, Sellas Life Sciences has recorded 72 events in its AML trial, nearing the 80-event threshold required to trigger the final survival analysis, which may indicate longer patient survival and boosts market confidence in the company.
- Strong Stock Performance: SLS shares surged to a three-year high on Monday, closing at $5.31 on Tuesday with over a 5% gain, having finished in the green in 11 of the last 12 sessions, reflecting strong investor anticipation for the upcoming clinical data.
- Analyst Optimism: Koyfin consensus estimates show an average 12-month price target of $6.83 for SLS, implying a 29% upside from current levels, with analysts rating the stock as a 'Strong Buy', indicating a positive outlook for its future performance.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for SLS is deemed 'extremely bullish', with message volume rising 47% over the past 24 hours, highlighting heightened investor interest and confidence in the forthcoming trial results.
See More
SELLAS GPS Trial Progress Captivates Investors
- Trial Progress: SELLAS Life Sciences' ongoing GPS trial is an overall survival study, with 72 deaths recorded as of December 26, nearing the expected 80, indicating potential extended patient survival that could positively impact the company's future market performance.
- Market Reaction: Retail investors on Stocktwits have shown extreme optimism for SELLAS stock, with discussion volume increasing by approximately 453% over the past 24 hours, reflecting strong anticipation for the upcoming trial results that could drive stock price appreciation.
- Analyst Ratings: According to Koyfin data, all three analysts covering SELLAS rate it 'Buy' or higher, with an average price target of $6.83, suggesting further upside potential for the stock, which bolsters investor confidence.
- CEO Insights: SELLAS CEO Angelos Stergiou noted that while the 80th event has not yet occurred, delays may increase the probability of a successful study, a viewpoint supported by key opinion leaders, further enhancing market confidence in the company.
See More
Sellas CEO Highlights Progress in Phase 3 REGAL Trial
- REGAL Trial Update: Sellas CEO referenced the nearing completion of the Phase 3 REGAL trial analysis on LinkedIn, indicating the potential of GPS as a therapy for Acute Myeloid Leukemia (AML), which could further boost stock prices.
- Increased Institutional Holdings: Anson Funds Management recently disclosed a 4.9% stake in Sellas, reflecting institutional confidence in the company's prospects and potentially attracting more investor interest.
- Retail Market Enthusiasm: Sellas stock surged over 15% on Monday to its highest level in over a month, reflecting strong bullish sentiment among retail investors regarding the upcoming REGAL trial results, with message volume on Stocktwits increasing nearly 170%.
- IMPACT-AML Partnership: Last month, Sellas partnered with IMPACT-AML to conduct a multi-site clinical study for SLS009, demonstrating the company's strategic positioning and market expansion potential in AML treatment.
See More
SELLAS Life Sciences Expands SLS009 Clinical Study with IMPACT-AML in Europe
- Clinical Study Expansion: SELLAS Life Sciences has signed an agreement with IMPACT-AML to expand the clinical development of SLS009 into Europe, with plans to enroll 40 newly diagnosed AML patients, aiming to accelerate patient enrollment and broaden drug accessibility.
- U.S. Enrollment Plans: The U.S. clinical trial is expected to begin in Q1 2026, with European enrollment anticipated in Q2 2026, demonstrating the company's commitment to advancing SLS009 on a global scale.
- Market Performance Decline: SLS stock has ended in the red in five of the last seven sessions, with the latest trading down 3.2%, as investors booked profits amid dilution concerns, putting pressure on the stock price.
- Investor Sentiment: Despite the stock's decline, retail sentiment on Stocktwits remains bullish, with investors believing that validating SLS009 in both the U.S. and EU simultaneously will attract global buyers like Novartis.
See More
SELLAS Life Sciences Partners with IMPACT-AML to Advance SLS009 Clinical Trials
- Clinical Trial Expansion: SELLAS Life Sciences has entered into an agreement with IMPACT-AML to recruit approximately 40 newly diagnosed high-risk acute myeloid leukemia (AML) patients in the U.S. by Q1 2026, leveraging existing infrastructure for efficient European patient enrollment.
- Drug Combination Evaluation: SLS009 will be evaluated in combination with azacitidine (AZA) and venetoclax (VEN), aiming to enhance treatment outcomes for newly diagnosed AML patients, which is expected to significantly improve clinical results.
- International Collaboration Network: The IMPACT-AML project connects multiple European clinical institutions, allowing SELLAS to accelerate clinical research in a cost-effective manner, thereby enhancing the market potential of SLS009.
- Strategic Significance: This collaboration not only provides strong external validation for SELLAS but also reflects the potential of SLS009 in addressing critical unmet needs in AML, further solidifying SELLAS's market position in cancer treatment.
See More
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
- IP Expansion: Oncolytics Biotech filed a Track 1 prioritized examination patent application with the USPTO in Q3 2025 for manufacturing innovations related to pelareorep, which, if granted, could extend its commercial protection to 2044, thereby enhancing its competitive market position.
- Significant Clinical Results: Pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 6-11% response rate for chemotherapy alone, potentially driving a $20 billion market growth.
- Expert Team Expansion: Oncolytics Biotech expanded its Gastrointestinal Tumor Scientific Advisory Board by adding three globally recognized experts from leading cancer centers, enhancing academic support for its clinical research and further elevating the company's reputation in the industry.
- Successful FDA Alignment: The company secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial planned for this disease in the market.
See More
Sellas Life Sciences Stock Soars Ahead of Key AML Trial Data
- Clinical Trial Progress: As of December 26, 2025, Sellas Life Sciences has recorded 72 events in its AML trial, nearing the 80-event threshold required to trigger the final survival analysis, which may indicate longer patient survival and boosts market confidence in the company.
- Strong Stock Performance: SLS shares surged to a three-year high on Monday, closing at $5.31 on Tuesday with over a 5% gain, having finished in the green in 11 of the last 12 sessions, reflecting strong investor anticipation for the upcoming clinical data.
- Analyst Optimism: Koyfin consensus estimates show an average 12-month price target of $6.83 for SLS, implying a 29% upside from current levels, with analysts rating the stock as a 'Strong Buy', indicating a positive outlook for its future performance.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for SLS is deemed 'extremely bullish', with message volume rising 47% over the past 24 hours, highlighting heightened investor interest and confidence in the forthcoming trial results.
See More
SELLAS GPS Trial Progress Captivates Investors
- Trial Progress: SELLAS Life Sciences' ongoing GPS trial is an overall survival study, with 72 deaths recorded as of December 26, nearing the expected 80, indicating potential extended patient survival that could positively impact the company's future market performance.
- Market Reaction: Retail investors on Stocktwits have shown extreme optimism for SELLAS stock, with discussion volume increasing by approximately 453% over the past 24 hours, reflecting strong anticipation for the upcoming trial results that could drive stock price appreciation.
- Analyst Ratings: According to Koyfin data, all three analysts covering SELLAS rate it 'Buy' or higher, with an average price target of $6.83, suggesting further upside potential for the stock, which bolsters investor confidence.
- CEO Insights: SELLAS CEO Angelos Stergiou noted that while the 80th event has not yet occurred, delays may increase the probability of a successful study, a viewpoint supported by key opinion leaders, further enhancing market confidence in the company.
See More
Sellas CEO Highlights Progress in Phase 3 REGAL Trial
- REGAL Trial Update: Sellas CEO referenced the nearing completion of the Phase 3 REGAL trial analysis on LinkedIn, indicating the potential of GPS as a therapy for Acute Myeloid Leukemia (AML), which could further boost stock prices.
- Increased Institutional Holdings: Anson Funds Management recently disclosed a 4.9% stake in Sellas, reflecting institutional confidence in the company's prospects and potentially attracting more investor interest.
- Retail Market Enthusiasm: Sellas stock surged over 15% on Monday to its highest level in over a month, reflecting strong bullish sentiment among retail investors regarding the upcoming REGAL trial results, with message volume on Stocktwits increasing nearly 170%.
- IMPACT-AML Partnership: Last month, Sellas partnered with IMPACT-AML to conduct a multi-site clinical study for SLS009, demonstrating the company's strategic positioning and market expansion potential in AML treatment.
See More
SELLAS Life Sciences Expands SLS009 Clinical Study with IMPACT-AML in Europe
- Clinical Study Expansion: SELLAS Life Sciences has signed an agreement with IMPACT-AML to expand the clinical development of SLS009 into Europe, with plans to enroll 40 newly diagnosed AML patients, aiming to accelerate patient enrollment and broaden drug accessibility.
- U.S. Enrollment Plans: The U.S. clinical trial is expected to begin in Q1 2026, with European enrollment anticipated in Q2 2026, demonstrating the company's commitment to advancing SLS009 on a global scale.
- Market Performance Decline: SLS stock has ended in the red in five of the last seven sessions, with the latest trading down 3.2%, as investors booked profits amid dilution concerns, putting pressure on the stock price.
- Investor Sentiment: Despite the stock's decline, retail sentiment on Stocktwits remains bullish, with investors believing that validating SLS009 in both the U.S. and EU simultaneously will attract global buyers like Novartis.
See More
SELLAS Life Sciences Partners with IMPACT-AML to Advance SLS009 Clinical Trials
- Clinical Trial Expansion: SELLAS Life Sciences has entered into an agreement with IMPACT-AML to recruit approximately 40 newly diagnosed high-risk acute myeloid leukemia (AML) patients in the U.S. by Q1 2026, leveraging existing infrastructure for efficient European patient enrollment.
- Drug Combination Evaluation: SLS009 will be evaluated in combination with azacitidine (AZA) and venetoclax (VEN), aiming to enhance treatment outcomes for newly diagnosed AML patients, which is expected to significantly improve clinical results.
- International Collaboration Network: The IMPACT-AML project connects multiple European clinical institutions, allowing SELLAS to accelerate clinical research in a cost-effective manner, thereby enhancing the market potential of SLS009.
- Strategic Significance: This collaboration not only provides strong external validation for SELLAS but also reflects the potential of SLS009 in addressing critical unmet needs in AML, further solidifying SELLAS's market position in cancer treatment.
See More
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
- IP Expansion: Oncolytics Biotech filed a Track 1 prioritized examination patent application with the USPTO in Q3 2025 for manufacturing innovations related to pelareorep, which, if granted, could extend its commercial protection to 2044, thereby enhancing its competitive market position.
- Significant Clinical Results: Pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 6-11% response rate for chemotherapy alone, potentially driving a $20 billion market growth.
- Expert Team Expansion: Oncolytics Biotech expanded its Gastrointestinal Tumor Scientific Advisory Board by adding three globally recognized experts from leading cancer centers, enhancing academic support for its clinical research and further elevating the company's reputation in the industry.
- Successful FDA Alignment: The company secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial planned for this disease in the market.
See More
